Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

RVNC CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces to Revance Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

Newsfile January 18, 2022

Lost Money in Revance Therapeutics, Inc.?

Business Wire January 18, 2022

Revance Therapeutics Shareholder Notice

Newsfile January 18, 2022

Shareholder Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 18, 2022

Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA

Business Wire January 18, 2022

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Investors

PR Newswire January 18, 2022

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

Newsfile January 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

PR Newswire January 17, 2022

Investor Action Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 17, 2022

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - RVNC

PR Newswire January 17, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - (RVNC)

Newsfile January 17, 2022

RVNC LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Revance Therapeutics, Inc.

Newsfile January 17, 2022

RVNC INVESTOR ALERT: Thornton Law Firm Reminds Revance Therapeutics Investors of Securities Class Action

Newsfile January 16, 2022

RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Limited Shareholders

Newsfile January 16, 2022

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

Newsfile January 16, 2022

Revance Therapeutics Update

Newsfile January 16, 2022

Revance Therapeutics Inc. News: Berger Montague Investigates Securities Fraud Allegations Against Revance Therapeutics Inc. (RVNC); Lead Plaintiff Deadline is February 8, 2022

Newsfile January 15, 2022

Revance Therapeutics Class Action Reminder

Newsfile January 15, 2022

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNC

Newsfile January 14, 2022

Shareholder Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 14, 2022